Compare AU
Compare DRUG vs. VGS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the Vanguard MSCI Index International Shares ETF (VGS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | VGS | |
|---|---|---|
Popularity | Low | High |
Pearlers invested | 63 | 11,904 |
Median incremental investment | $967.00 | $1,075.43 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,921.92 | $3,932.04 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | VGS | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | Vanguard MSCI Index International Shares ETF (ASX: VGS) seeks to track the performance of the MSCI World ex-Australia index before account fees, expenses and taxes. The index tracks the large and mid-cap stocks from 22 developed markets including the US, UK, Japan, Canada, France, Germany and Israel. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Apple Inc. (5.40 %) Microsoft Corp. (4.13 %) Amazon.com Inc. (2.15 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Information Technology (22.51 %) Financials (13.70 %) Health Care (12.53 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (72.93 %) Japan (5.73 %) United Kingdom of Great Britain and Northern Ireland (3.77 %) |
Management fee | 0.57 % | 0.18 % |
Key Summary
DRUG | VGS | |
|---|---|---|
Issuer | BetaShares | Vanguard |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | MSCI WorldexAustralia Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.18 % |
Price | $8.25 | $140.24 |
Size | $182.401 million | N/A |
10Y return | N/A | 169.17 % |
Annual distribution yield (5Y) | 1.90 % | 2.37 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 20/11/2014 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | VGS | |
|---|---|---|
Popularity | Low | High |
Pearlers invested | 63 | 11,904 |
Median incremental investment | $967.00 | $1,075.43 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,921.92 | $3,932.04 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | VGS | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | VGS |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |